These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30256926)

  • 1. Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty.
    Gregory MH; McKinnon A; Stwalley D; Hippensteel KJ; Loftus EV; Ciorba MA; Olsen MA; Deepak P
    J Crohns Colitis; 2019 Feb; 13(2):182-188. PubMed ID: 30256926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of pneumonia among patients with inflammatory bowel disease.
    Long MD; Martin C; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.
    Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis.
    Westerouen van Meeteren MJ; Hayee B; Inderson A; van der Meulen AE; Altwegg R; van Hoek B; Pageaux GP; Stijnen T; Stein D; Maljaars PWJ
    J Crohns Colitis; 2017 Sep; 11(9):1146-1151. PubMed ID: 28482085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
    Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease.
    Lee WJ; Lee TA; Calip GS; Suda KJ; Briars L; Schumock GT
    Inflamm Bowel Dis; 2018 Mar; 24(4):883-891. PubMed ID: 29562275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
    Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis.
    Khan N; Vallarino C; Lissoos T; Darr U; Luo M
    Inflamm Bowel Dis; 2020 Feb; 26(3):462-468. PubMed ID: 30980714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.
    Wintzell V; Svanström H; Melbye M; Jess T; Olén O; Ludvigsson JF; Pasternak B
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):845-853. PubMed ID: 31494100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease.
    Gholam-Mostafaei FS; Yadegar A; Aghdaei HA; Azimirad M; Daryani NE; Zali MR
    Curr Res Transl Med; 2020 Aug; 68(3):125-130. PubMed ID: 32414632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Bowel Diseases Increase the Risk of Periprosthetic Joint Infection.
    Chisari E; D'Mello D; Sherman MB; Parvizi J
    J Bone Joint Surg Am; 2022 Jan; 104(2):160-165. PubMed ID: 34648464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Park KT; Sceats L; Dehghan M; Trickey AW; Wren A; Wong JJ; Bensen R; Limketkai BN; Keyashian K; Kin C
    Aliment Pharmacol Ther; 2018 Aug; 48(3):340-346. PubMed ID: 29876995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Lai JC; Sandborn WJ; Moore AA
    Inflamm Bowel Dis; 2021 Oct; 27(10):1626-1633. PubMed ID: 33325507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.